Further studies are needed to elucidate the clinical benefits of multiple anti‐HER2 therapies in combination with endocrine therapy against HER2 mutant, ER+ breast tumors in less heavily pretreated patients. This evidence concerns the gene ERBB2 and breast neoplasm.